看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。2 g* u9 D, u! B& A0 Z6 J; d
$ J$ O4 l1 I* F
9 R- F: i9 h& P, Y8 RCurrently available feasibility data for possible combination strategies. 5 r3 F! b: a5 w( c/ v7 I( P- T J
————————————————————————————————- ~5 N# R6 } G6 b' q% _5 U# C& c
Combination Feasibility according to preliminary data & P# A7 ?9 h$ e$ ]7 e5 @
——————————————————————————————————2 K4 M% u3 J' _' c
Bevacizumab + sorafenib Yes, reduced dose
9 D; v& J+ l' x( ~4 T9 z3 UBevacizumab + sunitinib† No
, B/ v7 U5 t3 hBevacizumab + temsirolimus Yes $ N) i2 e) Z3 K" g$ s+ M
Bevacizumab + everolimus Yes
/ a; D+ w, J: x; D- Z0 fSorafenib + sunitinib ? $ H8 @7 h. z0 ]3 H$ F* \6 f, M2 h
Sorafenib + temsirolimus Yes, reduced dose
* S8 K, u1 w( F* N6 l# o5 TSorafenib + everolimus Yes, reduced dose ! V, j& q6 o S L/ T a9 ^1 J
Sunitinib + temsirolimus† No
6 b- Y/ c) ]0 J2 @8 `; v" gSunitinib + everolimus ? ' p' F U) b6 z1 E# c
Temsirolimus + everolimus ? / I. j4 k& e* n2 R% }
————————————————————9 N0 ]3 `* J* U) b
†Led to US FDA warning.
4 B2 o/ k) G' {! Y+ _' Z?: As yet unattempted combination.
- s1 Q a _/ R1 t- ?1 \ |
显身卡
